Discontinuation of GLP-1 drugs linked to doubled risk of heart attack, stroke or death in Italian type 2 diabetes cohort
Just the facts

Discontinuation of GLP-1 drugs linked to doubled risk of heart attack, stroke or death in Italian type 2 diabetes cohort

Summary

An Italian retrospective cohort study found that patients with type 2 diabetes who stopped GLP-1 receptor agonists experienced roughly twice the rate of major cardiovascular events and a five-fold increase in all-cause mortality compared with those who remained on therapy.

A retrospective cohort study using data from 301 diabetes clinics in Italy between 2004 and 2024 examined outcomes in 80,302 patients with type 2 diabetes who had received at least one prescription for a glucagon-like peptide-1 receptor agonist (GLP-1RA). Participants who did not receive a GLP-1RA prescription at two consecutive visits were classified as discontinuers, while those with ongoing prescriptions were considered persistent users.

After matching, each group comprised 28,713 individuals. Over a mean follow-up, the incidence of the composite endpoint—non-fatal myocardial infarction, non-fatal stroke or death from any cause—was 3.94 events per 100 person-years among discontinuers versus 1.96 events per 100 person-years among persistent users, indicating roughly a two-fold higher risk after stopping therapy. All-cause mortality was 0.48 per 100 person-years for persistent users compared with 2.23 per 100 person-years for those who discontinued, a nearly five-fold increase.

The association persisted in sensitivity analyses and was more pronounced in participants with obesity. Measured cardiovascular risk factors such as weight, blood glucose, lipids and blood pressure showed only modest changes after discontinuation, suggesting that the observed risk elevation may extend beyond conventional risk-factor control.

The authors noted that the study is observational and cannot establish causality. Unmeasured factors—such as underlying frailty, malignancy, socioeconomic status or reasons for stopping treatment—could contribute to the higher mortality. They also highlighted that the analysis excluded patients with prior major cardiovascular events and did not include newer agents like tirzepatide.

The findings underscore the need for prospective research to determine whether continued GLP-1RA therapy confers protective benefits beyond glycaemic and weight effects, and to identify strategies that reduce discontinuation rates, which range from 20 % to 50 % within the first year of treatment.

Keep reading — for free

Create a free account to follow the news. No card required.